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The implementation of severe combined immunodeﬁciency (SCID) newborn screening
has played a pivotal role in identifying these patients early in life as well as detecting various
milder forms of T cell lymphopenia (TCL). In this study we reviewed the diagnostic and
clinical outcomes, and interesting immunology ﬁndings of term infants referred to a tertiary
care center with abnormal newborn SCID screens over a 6-year period. Key ﬁndings
included a 33% incidence of non-SCID TCL including infants with novel variants in FOXN1,
TBX1, MYSM1, POLD1, and CD3E; 57% positivity rate of newborn SCID screening
among infants with DiGeorge syndrome; and earlier diagnosis and improved transplant
outcomes for SCID in infants diagnosed after compared to before implementation of
routine screening. Our study is unique in terms of the extensive laboratory workup of
abnormal SCID screens including lymphocyte subsets, measurement of thymic output
(TREC and CD4TE), and lymphocyte proliferation to mitogens in nearly all infants. These
data allowed us to observe a stronger positive correlation of the absolute CD3 count with
CD4RTE than with TREC copies, and a weak positive correlation between CD4RTE and
TREC copies. Finally, we did not observe a correlation between risk of TCL and history of
prenatal or perinatal complications or low birth weight. Our study demonstrated SCID
newborn screening improves disease outcomes, particularly in typical SCID, and allows
early detection and discovery of novel variants of certain TCL-associated
genetic conditions.
Keywords: newborn screen (NBS), severe combined immune deﬁciency (SCID), TREC, lymphopenia, digeorge
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we assessed the signiﬁcance of prenatal complications and birth
weight in relation to the incidence of TCL.

INTRODUCTION
Severe combined immunodeﬁciency (SCID) comprises a broad
group of genetic disorders of the adaptive immune system in
which T cell, and sometimes B and NK cell, development and
function are impaired. Patients are susceptible to severe
opportunistic infections starting in the ﬁrst months of life and
do not survive past 1 year of age without intervention (1). Overall
incidence of SCID has been shown to be roughly 1:58,000 based
on 11 screening programs in the United States (2).
SCID newborn screening by the T cell receptor excision circle
(TREC) assay is a measure of T cell receptor gene rearrangement
and, thus, a marker of naïve T cell production by the thymus. In
the United States screening was ﬁrst implemented in Wisconsin
in 2008, and in all 50 states by 2018. This has allowed for earlier
diagnosis and treatment, typically with hematopoietic stem cell
transplant, gene therapy, or enzyme replacement, and has led to
improved survival of infants with SCID (2–6). These outcomes
are highlighted in a study from the Primary Immune Deﬁciency
Treatment Consortium which found 94% survival among infants
who were transplanted by 3.5 months age, versus 50% survival
among those who had active infection and were transplanted
later than 3.5 months age (7).
SCID screening has also led to the detection of various types
of non-SCID, or idiopathic, T cell lymphopenia (TCL) of which
the clinical implications and outcomes have been less clear (4, 8).
Some of the conditions responsible for non-SCID TCL include
chromosome abnormalities, cardiac or gastrointestinal
anomalies, prematurity, and prenatal factors such as maternal
diabetes or use of immunosuppressive medications (1, 2). In
cases where no clear syndrome or genetic cause of SCID is
identiﬁed, leading to a diagnosis of idiopathic TCL, the decision
of whether hematopoietic stem cell transplant (HSCT) would be
beneﬁcial becomes challenging, and is guided by the speciﬁc
immunologic ﬁndings in the patient and their evolution over
time (9). Though some infants have persistent TCL beyond 2
years of age, others are only transiently lymphopenic, as found by
one referral center in New York (10).
SCID screening algorithms and TREC cutoff values vary
among different programs, with less stringent threshold values
generally allowing for increased detection of non-SCID TCL
cases (11). By correlating TRECs with T lymphocyte subsets at
the population level, immunologists and public health ofﬁcials
can adjust TREC cutoff values on the newborn screen to most
efﬁciently identify those with TCL (5). Although the correlation
between TREC levels and T cell counts is generally strong, it is
not always consistent (8, 12).
In this study, we characterize the diagnostic and clinical
outcomes of 154 infants referred to St. Louis Children’s
Hospital Immunology clinic with positive newborn SCID
screens from Missouri and Illinois between July 2014 and
March 2020. In doing so, we identiﬁed several unique gene
variants associated with non-SCID TCL that were not previously
reported. We also analyzed a broad range of immunological
laboratory data for all infants in the study including lymphocyte
subpopulations, TREC copies, CD4+ T cell recent thymic
emigrants (CD4RTE), and naïve CD4+ cell percentage. Finally,
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METHODS
Data was collected on patients referred from Illinois and
Missouri. The newborn SCID screening program started in
July 2014 in Illinois and in January 2017 in Missouri. Both
states utilize an in-house multiplex assay involving the CDC in
situ method for detection of TREC by RT-PCR with RNaseP as
the control. Our institution is one of 3 referral centers in
Missouri for positive SCID screens and receives roughly a third
of the total statewide referrals. Referrals are made based on
patient and primary care provider preference and not on the
TREC level or any geographical restrictions. While the
proportion of Illinois referrals that we receive is unclear, these
patients generally reside in southern Illinois, where our
institution is the nearest SCID referral center. Newborn
screening data at the state level is organized by specimen
rather than by patient so the total number of individuals
screened statewide was unavailable. A positive newborn screen
for SCID in Illinois was deﬁned as a TREC level of 250 copies/mL
or less, and in Missouri as a cycle threshold value of 37 or greater.
Of note, prior to January 2019 a cycle threshold value of 36 or
greater was considered positive in Missouri, and prior to May
2015 a TREC level of 300 copies/mL or less was considered
positive in Illinois. Cycle thresholds greater than 39 or TREC
levels less than 25 copies/mL were considered high risk and
resulted in immediate referral for further workup instead of
repeating the newborn screen.
Data for our study population was compiled from IRBapproved retrospective electronic medical record review of
infants referred between July 2014 and January 2018 and a
prospective primary immunodeﬁciency database of patients
from January 2018 until March 2020. We excluded premature
patients if their positive screen normalized when repeated after
36 weeks corrected gestational age. Demographic information,
relevant clinical history, and laboratory work from their initial
clinical evaluation and follow up visits were reviewed. Laboratory
studies from the initial evaluation included CBC with differential,
quantitation of lymphocyte subpopulations, TREC copy number
analysis normalized to CD3+ T cell count, absolute CD4RTE
(recent thymic emigrant, deﬁned as CD4+ CD45RA+ CD31+ T
cells), and naïve Th cell percentage (deﬁned as percentage of
CD4+ CD45RA+ cells out of the total CD4+ cells). Results of
chromosome microarray, targeted gene panels (GeneDx® SCID
panel or Invitae® Primary Immunodeﬁciency panel), and whole
exome sequencing were also reviewed if obtained for clinical
care. Diagnostic outcomes were classiﬁed into 3 groups including
1) severe T cell deﬁciency due to SCID and complete DiGeorge
phenotype, 2) non-SCID TCL either due to known genetic or
secondary causes or idiopathic, and 3) normal T cell count. For
the ﬁrst category, SCID was further characterized as typical or
leaky SCID. Typical SCID was deﬁned as having CD3+ T cells <
300 cells/mL, less than 10% of the lower range of normal
proliferation to phytohemaglutinin, and/or detectable maternal
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TABLE 1 | Demographic and diagnostic characteristics of infants with positive
newborn SCID screens.
Demographic characteristic (N=154)
Male
Race
White
Black
Asian
Other/Unknown
States where newborn screening obtained
Illinois
Missouri
Pre/peri-natal complications
Mean age at initial evaluation
Diagnostic categories
Normal ﬁndings
No T cell lymphopenia
Normal CD3 but other cell lines abnormal
Repeat newborn screen normal
Non-SCID TCL
Non-SCID TCL with genetic or secondary cause
Idiopathic non-SCID TCL
SCID and other severe TCL
Typical SCID
Leaky SCID
Complete DiGeorge

determine the differences in these variables between the
normal T cell count and non-SCID TCL groups. Data is
presented as mean ± standard deviation and range for
quantitative variables. Pearson’s correlation coefﬁcient (r) was
calculated to assess correlations between two continuous lab
values. Paired T-test was used to assess the differences in lab
values between normal and non-SCID TCL groups. Data was
analyzed by SAS® (SAS Institute Inc., Cary, NC, USA) 9.4
version. A P-value < 0.05 was considered statistically signiﬁcant.

N (%)
111 (72)
95 (62)
51 (33)
1 (0.6)
7 (5)
76 (49)
78 (51)
54 (35)
22 days

RESULTS
A total of 154 infants were included in the study as shown in
Table 1. Of these, 72% were male, 62% were Caucasian, and 33%
were African-American. 51% were from Missouri and the rest
from Illinois. 3% were premature but had persistently abnormal
newborn SCID screening at 36 weeks corrected gestational age or
later. The mean age at initial evaluation was 22 days (1-86 days).
60% of infants had a normal CD3+ T cell count (N=91) or
normal repeat newborn screen (N=2), and their repeat TREC
copy number analysis normalized to CD3+ T cell count was
normal or near-normal in all 84 infants tested (Figure 1). Prior
to January 2019, when Missouri’s cycle threshold cutoff for a
positive SCID screen was increased, this false positive rate was
slightly higher at 69%. 33% of infants had non-SCID TCL (mild,
N=26 and moderate, N=25), and 6% had typical SCID (N=6),
leaky SCID (N=3) or complete DiGeorge phenotype (N=1).

93 (60)
74 (48)
17 (11)
2 (1)
51 (33)
26 (17)
25 (16)
10 (6)
6 (4)
3 (2)
1 (0.6)

T cell engraftment. Leaky SCID was deﬁned as having a CD3+ T
cell count of >300 cells/mL, but with a restricted TCR repertoire
and/or lack of naive T cells (3). For the second category, nonSCID TCL was deﬁned as having CD3+ T cells < 2,500 cells/mL,
and further classiﬁed as mild (CD3+ T cells >1,500-2,500
cells/mL) or moderate (CD3+ T cells 300-1,500 cells/mL).
Idiopathic TCL was deﬁned as non-SCID TCL without a
known underlying genetic or secondary cause, in some cases
based on negative chromosome microarray, whole exome
sequencing, and/or targeted genetic testing (3, 8).
Statistical analysis was performed to identify correlations
between CD3+ T cell count, TREC, CD4RTE, naïve Th cell
percentage, and absolute lymphocyte count (ALC), and to

Causes of Non-SCID T-Cell Lymphopenia
and Their Outcomes
Twenty-six infants had non-SCID TCL with a known genetic or
secondary cause, of which 20 had moderate and 6 had mild TCL.
All had follow-up visits at a median age of 14 months (10 days –
59 months) except for 1 patient with trisomy 21 for whom
immunology follow up was recommended as needed. Genetic
etiologies included 22q11 deletion (N=16), trisomy 21 (N=2),

FIGURE 1 | TREC copies by age at the time of testing in term infants with abnormal SCID screens and normal CD3+ T cell count. Dashed line represents normal
cutoff TREC value for term infants.
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chromosome microarray to rule out partial DiGeorge syndrome.
This showed a 1q21.1 microduplication that was not felt to be
related to his lymphopenia. Additionally, 1 infant had a
hospitalization for periorbital cellulitis requiring 1 day of IV
antibiotics, and another had a PICU admission for RSV infection
without bacterial superinfection. None of the infants with
idiopathic TCL required antimicrobial prophylaxis or
immunoglobulin replacement.
Individual T lymphocyte trends of non-SCID TCL infants
from the time of initial evaluation until as late as 30 months age
are shown in Figure 2. Among infants with non-SCID TCL with
a known genetic or secondary cause, T cell counts rose in 50% of
infants from an average of 1133 ± 626 cells/mL to 1778 ± 544
cells/mL and dropped in the other 50% of infants from an average
of 1206 ± 478 cells/mL to 930 ± 357 cells/mL. Among infants with
idiopathic TCL, T cell counts rose in 75% of infants from an
average of 1644 ± 564 cells/mL to 2288 ± 841 cells/mL and
dropped in the other 25% of infants from an average of 2013 ±
304 cells/mL to 1550 ± 535 cells/mL. Four of the infants that
improved had normalization of T cell count to 2500 cells/mL or
greater by a median age of 5.1 months (4-7.3 months).

and genetic variants presumed to be pathogenic in TBX1 (N=2),
FOXN1 (N=1), MYSM1 (N=1), CD3E (N=1), ATM (N=1), and
POLD1 (N=1). Three infants with 22q11 deletion died, including
1 preterm infant who died from necrotizing enterocolitis, and 2
term infants who had complicated post-operative courses and
cardiac arrest following surgery for their congenital heart disease.
Six infants, all with 22q11 deletion, had recurrent infections or
hospitalization for infections, and 1 patient has required
treatment with immunoglobulin replacement therapy and
antibacterial prophylaxis.
All patients in our cohort with monogenic variants felt to be
likely pathogenic are summarized in Table 2, including 5
patients with novel variants associated with non-SCID TCL. P1
had progressively worsening pancytopenia requiring
hematopoietic stem cell transplant and ultimately passed away
from hepatic veno-occlusive disease in the post-transplant
period. P2 and P3 had improving or relatively stable T cell
counts over time and no signiﬁcant infections. P5 had 2
pathogenic bi-allelic variants for which his parents were found
to be heterozygous carriers, thereby conﬁrming his diagnosis of
ataxia-telangiectasia associated with T and B cell lymphopenia.
While his newborn screen showed a mildly low level of 217.6
TREC copies/mL, his identical twin brother had a normal screen
with 368.8 TREC copies/mL. The twin brother also had the same
pathogenic variants, T and B cell lymphopenia, and elevated AFP
level conﬁrming the diagnosis of ataxia-telangiectasia. P6 had a
heterozygous variant of uncertain signiﬁcance that was absent in
both her parents. This patient had abnormal DNA repair based
on radiosensitivity testing at 6 weeks age. In addition to
lymphopenia, she had anemia requiring transfusions in the
ﬁrst month of life. She was started on immunoglobulin
replacement and antimicrobial prophylaxis and has not had
any infections. At 17 months, her radiosensitivity testing
normalized, and her CD4+ T cell count remains low but has
improved from 398 cells/mL at 2 weeks of age to 1083 cells/mL at
17 months. P7 had improving T cell count and her TCL resolved
at 11 months of age. She was doing well without infections.
One patient had a secondary cause of non-SCID TCL due to
congenital thoraco-cervical ﬁbrosarcoma who underwent
resection of the mass in the immediate postnatal period. His
CD3+ T cell counts signiﬁcantly improved over time from 393
cells/mL initially to 1849 cells/mL, suggesting that mass effect
from the ﬁbrosarcoma had impaired his thymic development,
resulting in a DiGeorge-like phenotype.
Twenty-ﬁve infants in our study had idiopathic non-SCID
TCL, of which 5 had moderate and 20 had mild TCL, and
all had normal CD3 + T cell proliferative responses to
phytohemagglutinin and pokeweed. Six infants were lost to
follow up, 1 transferred care to a different institution, and 2
did not require follow up. Among the 16 patients that did follow
up at a median age of 5 months (2.5-26 months), 7 had a normal
chromosome microarray or FISH testing for DiGeorge syndrome
and 3 had negative SCID genetic testing. Only 2 infants with
idiopathic TCL had recurrent infections – 1 with recurrent ear
infections that improved after tympanostomy tube placement,
and 1 with recurrent upper respiratory infections prompting a
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SCID Screening Outcomes in DiGeorge
Syndrome
During the 6-year study period, our institution cared for a total
of 28 infants with DiGeorge syndrome (DGS) including 26
infants with 22q11.2 deletion and 2 infants with heterozygous
pathogenic variants in TBX1 who had undergone newborn SCID
screening (Table 3 and Figure 3). Sixteen infants (57%) had an
abnormal SCID screen, and those patients had a lower median
CD3+ T cell count compared to infants with normal SCID
screens: 1124 (954-1392) cells/mL vs. 2116 (1143-2690) cells/mL
respectively, p=0.024. TCL was present in a higher percentage of
the infants with abnormal screens than those with normal
screens: 94% vs. 33% respectively, p=0.001. However, the age at
blood draw for the ﬁrst T cell count was different between the
groups, with a median age of 12 days (range 1-86 days) in DGS
infants with abnormal SCID screen and a median age of 90 days
(range 7-367 days) in DGS infants with normal SCID screen.
Four of them were brought to medical attention solely based on
the abnormal newborn screen, including 1 patient who was later
found to have signiﬁcant congenital heart disease requiring lifesaving intervention.
Of the 12 DGS patients with normal SCID screen, clinical
presentations that led to DGS diagnosis were congenital heart
diseases (n=6), failure to thrive and feeding difﬁculty (n=2),
prenatal diagnosis due to abnormal fetal ultrasound (n=2),
congenital diaphragmatic hernia (n=1), and developmental
delay (n =1). After exclusion of two patients who were
prenatally diagnosed, the age at DGS diagnosis in infants with
normal SCID screen ranged from 3 days to 10 months, with a
median age of 39 days. Of 16 DGS patients with abnormal SCID
screen, after exclusion of 5 infants who were prenatally
diagnosed, the age at DGS diagnosis ranged from 2 to 95 days,
with a median age of 30 days.

4
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Patient

Coordinates
(Build hg38)

Non-SCID TCL
P1
1:58667227

Gene

MYSM1*† c.1843-1G>A
(NM_001085487.2)

P2
P3

17:28530824
22:19763331

FOXN1*†
TBX1*

P4
P5

22:19765069
11:108257471
11:108301698
19:50409228
11:118315498

TBX1
ATM

P6
P7
SCID
P8

POLD1*†
CD3E*†

Zygosity and inheritance if
known

IVS15-1G>A

Homozygous; paternal
uniparental disomy of
chromosome 1
p.Glu303Serfs*247 Heterozygous; maternal
p.Lys168ArgfsX2
Heterozygous; paternal

33

N/A

Pancytopenia

33
33

N/A
N/A

Isolated TCL
Isolated TCL
Isolated TCL
T and B cell lymphopenia

5

N/A
0.000006569
0.000006576
N/A
0.00009880

IVS6-2A>G
p.Asp144Val
N/A
p.Trp81Leu
p.Gly216Arg

Heterozygous
Heterozygous
Heterozygous
Heterozygous
Homozygous

34
25.9

N/A
0.000006571
N/A
N/A
0.00005257

T-B+NK-

N/A
N/A

T-B+NK+
T-B+NK-

28.1

0.00001972

T-B+NK+ leaky SCID

16.66
22.3

N/A
N/A

CHARGE syndrome and complete DiGeorge
phenotype with absent T cells, low B cells, low
NK cells

IL2RG
IL2RG

c.421C>T (NM_000206.2)
c.391C>T (NM_000206.2)

p.Gln141Ter
p.Gln131Ter

Hemizygous
Hemizygous

Other severe TCL
P14
11:36573831

RAG1

c.527G>T (NM_000448.2)

p.Cys176Phe

CHD7*†
RMRP†

c.2698-11A>G (NM_017780.3)
r.247G>C (NR_003051.3)

Intronic
N/A

Homozygous; maternal and
paternal
Heterozygous
Heterozygous

8:60821779
9:35657772

Immune phenotype

41
31
25.9
27
29.8

X:71110537
X:71110567

P15

Allele Frequency in
population
(Gnomad)

Heterozygous
Heterozygous; maternal
Heterozygous; paternal
Heterozygous; de novo
Heterozygous

ADA

JAK3*

CADD

p.Glu266Ter
Intronic
p.Thr1743Ile
p.Arg667Trp
p.Gly194Ser

20:44623039

P10 and P11
(Siblings)
P12
P13

JAK3*

c.907delG (NM_003593.2)
c.498_501dupCGAT
(NM_080647.1)
c.796G>T (NM_080647.1)
c.2251-10T>G
c.5228C>T (NM_000051.3)
c.1999C>T (NM_002691.3)
c.580G>A (NM_000733.3)

Protein change

c.862-2A>G
c.431A>T † (NM_000215.3)
Exon 10 deletion
c.242G>T (NM_000215.3)
c.646G>A (NM_000022.2)

P9

19:17841764
19:17843162
19:17843843

Coding change

26.3
27.4
33
35
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TABLE 2 | Monogenic variants detected in patients with non-SCID TCL and SCID or other severe TCL.

T and B cell lymphopenia
Isolated TCL
T-B+NK+

T-B-NK-

*Novel variant at time of diagnosis. †Variant of uncertain signiﬁcance.
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A

B

FIGURE 3 | Distribution of absolute T cell counts among infants with 22q11
deletion and either abnormal or normal newborn SCID screening.

done on the younger sibling; however, he had an undetectable
ADA1 enzyme level conﬁrming the diagnosis ADA deﬁciency.
The ALC ranged from 100 to 880 cells/mL (median of 450
cells/mL) in these 6 infants. All underwent HSCT at a median
age of 5 weeks (3 weeks – 4 months). All patients had full
engraftment of donor T cells at 6 months and 1 year posttransplant, with the exception of patient P10 who required 2
repeat transplants as a result of graft failure by 6 months
following the initial transplant. None of the patients had
infections prior to transplant, with the exception of P11, a
patient with ADA-SCID (sibling of P10) who had two
observational hospitalizations for rhino/enterovirus and
parainﬂuenza upper respiratory infection, neither of which
required any respiratory support. In contrast, the 4 infants
diagnosed with typical SCID at our institution prior to
newborn SCID screening (2008 – 2014) had a median age of
13 months (4-22 months) at transplant (Table 4). Three had
successful engraftment of donor T cells at 6 months and 1 year
post-transplant, but two patients required repeat transplants at 2
and 7 years of age due to poor immune reconstitution and T cell
exhaustion, respectively. The fourth patient had failed
engraftment at 6 months requiring a repeat transplant. All
patients had infections at initial presentation.
Three infants in our study were diagnosed with leaky SCID.
Their ALC ranged from 600 to 1300 cells/mL. P14 had a
homozygous RAG1 pathogenic variant as well as POMT1associated muscle-eye-brain disease. In this case, the parents
elected to postpone transplant due to underlying neurological
condition. She died at 17 months from sepsis associated with
ventriculoperitoneal shunt infection. Another patient had
unrevealing genetic workup including whole exome sequencing
and a targeted SCID genetic panel, which showed heterozygous
variants of unknown signiﬁcance in DOCK2 and Artemis that are
typically associated with autosomal recessive disease. However,
he had abnormal radiosensitivity testing and persistent
lymphopenia, and underwent HSCT at 6 months of age with

FIGURE 2 | T lymphocyte trends in patients with non-SCID TCL due to
genetic causes (A) and idiopathic TCL (B). Dashed lines indicate cutoffs for
mild (1500-2500 cells/mL) and moderate (300-1500 cells/mL) TCL. Data sets
represented by stars in Figure 1A indicate the patients with novel pathogenic
variants at the time of diagnosis.

TABLE 3 | Results of newborn SCID screening in infants with 22q11 deletion
syndrome diagnosed during the 6-year study period.
Parameters

Median CD3+ T cells/mL (IQR)
Number of infants with CD3+
T cells < 1500 (%)

Total infants with 22q11 deletion
(N=28)
Abnormal SCID
screen (N=16)

Normal SCID
screen (N=12)

1124 (954-1392)
15 (94%)

2116 (1143-2690)
4 (33%)

Pvalue

0.024
0.001

Diagnostic Outcomes for SCID and
Comparison of Outcomes Before/After
Screening
Six infants were diagnosed with typical SCID by newborn
screening due to pathogenic variants in JAK3 (N=2), ADA
(N=2), and IL2RG (N=2) as listed in Table 2. Two patients
with ADA deﬁciency were siblings, and genetic testing was not
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full engraftment at 6 months post-transplant. The third infant
had negative genetic workup including chromosome microarray,
clinical whole exome sequencing, and targeted SCID genetic
testing. Research-based T cell development testing suggested
intrinsic hematopoietic abnormalities (13), and he underwent
HSCT at 5 months of age, with full engraftment at 1 year posttransplant. One infant with leaky SCID who is not included in
the total study population of 154 infants was found to have an
IL2RG mutation despite a normal newborn SCID screen (14). It
is challenging to compare outcomes in patients with leaky SCID
before and after implementation of SCID screening as we had
only one patient with leaky SCID prior to implementation of
SCID newborn screening.
Patient P15 with CHARGE syndrome and complete
DiGeorge phenotype underwent thymic transplant, however
none of the other patients with primary thymic defects such as
P2, P3, or P4 had severe T cell lymphopenia or signiﬁcant T cell
dysfunction to require a thymic transplant.

Engraftments at 6 months and 1 year post-transplant, if available, were assessed. Repeat transplants were performed following failed engraftment at 6 months after the initial transplant or at later time points if indicated below.
*One infant with RAG1 deﬁciency who was initially managed at an outside institution prior to his transplant. A patient with IL2RG deﬁciency who was missed from newborn screening was not included as an outlier.

Engrafted at 6 months (1), engrafted at 6 months and 1
year (1), engrafted after 1 repeat transplant (1), deferred
transplant and died from sepsis (1)
Engrafted at 6 months (1), engrafted at
6 months and 1 year (4), engrafted after
2 repeat transplants (1)
Engrafted at 6 months and 1 year (1), engrafted after 1 repeat Engrafted at 6
transplant (1), engrafted at 6 months and 1 year but required months but died later
repeat transplant >1 year later (2)
of unclear etiology

13 days (2-28 days)
RAG1 (2), negative genetic workup (2)
6 months (5-6 months)
17 months (9 months – 3 years)
10 months (3-19 months)
IL2RG (2), PNP (1), RMRP (1)
13 months (4-22 months)
5 years (4-7 years)

1 month
RAG1
3 months
11 months

9 days (5-18 days)
JAK3 (2), IL2RG (2), ADA (2)
5 weeks (3 weeks – 4 months)
3 years (9 months – 5 years)
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Median age at diagnosis
Genetic etiology
Median age at transplant
Median age at most
recent follow-up
Outcomes

Leaky SCID (N=4*)
Typical SCID (N=4)

Before newborn screening
Parameters

TABLE 4 | Transplant outcomes for SCID and leaky SCID at SLCH 2015-present.

Leaky SCID (N=1)

Typical SCID (N=6)

After newborn screening

Mantravadi et al.
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Correlations Between Parameters
Measuring Thymic Output
Pairwise correlations between the total CD3 count, TREC copy
number normalized to CD3 count, absolute CD4RTE, naïve Th
cell percentage, and ALC were calculated using the total study
population, excluding patients with undetectable or 0 TREC
copies (Table 5 and Figure 4). All correlations were signiﬁcantly
positive, except for that between ALC and TREC copies, and the
strongest correlation was between CD4 RTE and CD3 count
(r=0.80, p<0.0001). Signiﬁcant moderate positive correlations
were found between TREC copies and naïve Th cell percentage
and between CD4 RTE and naïve Th cell percentage, while
signiﬁcant weak positive correlations were found between TREC
copies and CD3 count and between TREC copies and CD4RTE.
ALC correlated strongly with CD3 count and moderately with
CD4RTE and naïve Th cell percentage. When comparing the
normal T cell count, non-SCID TCL with known genetic or
secondary cause, and idiopathic TCL groups, signiﬁcant
differences in all lab parameters were found between the nonSCID TCL with known genetic cause and normal groups, as
shown in Table 6. However, only CD4RTE and ALC were
signiﬁcantly different between the idiopathic TCL and
normal groups.

TABLE 5 | Pairwise correlations between immunologic parameters of interest.
Correlation

TREC copies and absolute CD3
TREC copies and naïve Th cell percentage
TREC copies and CD4RTE
CD4 RTE and absolute CD3
CD4 RTE and naïve Th cell percentage
ALC and absolute CD3
ALC and TREC copies
ALC and CD4RTE
ALC and naïve Th cell percentage

Pearson’s correlation
coefﬁcient

P-value

0.25
0.44
0.36
0.80
0.50
0.75
0.17
0.59
0.45

0.0047
<0.0001
0.0001
<0.0001
<0.0001
<0.0001
0.0612
<0.0001
<0.0001

Patients with undetectable or 0 TREC copies were excluded from the correlations.
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FIGURE 4 | Pairwise correlations between immunologic parameters of interest.
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TABLE 6 | Comparison of immunologic parameters of interest between infants with normal T cell count, non-SCID TCL due to genetic or secondary causes, and
idiopathic TCL.
Lab value
TREC copies per 106 T cells
CD4 RTE (cells/mL)
Naïve Th cell percentage
ALC (103 cells/mL)

Normal (N=88)

Non-SCID TCL due to genetic or secondary cause (N=26)

Idiopathic TCL (N=25)

15548.14 ± 7800.03

8406.48 ± 3733.40
P = 0.0001
598.84 ± 497.59
P < 0.0001
79 ± 12.13
P = 0.0014
2.7 ± 1.5
P < 0.0001

14296.48 ± 8058.81
P = 0.49
850.88 ± 363.51
P < 0.0001
84.21 ± 6.23
P = 0.32
3.2 ± 0.9
P < 0.0001

1547.2 ± 631.35
85.73 ± 6.53
4.8 ± 1.5

P-values reﬂect comparison with the normal T cell count group.

that out of 13 total abnormal newborn SCID screens that year, 5
(38%) were due to non-SCID TCL and 1 (7.7%) due to SCID. In
comparison, the positive predictive value of newborn screening
for TCL was 48% in Wisconsin (15), 38% in California (5), and
20.3% in New York (16). The variation in these rates can be
attributed to the differences in screening algorithms and testing
thresholds for TCL between different states (2). As expected, the
positive predictive value of SCID newborn screens at our
institution was higher prior to 2019 when Missouri’s cycle
threshold cutoff was lower.
Of note, three quarters of infants referred to our center in this
study were male, suggesting an increased prevalence of TCL in
males compared to females, the reason for which is unclear
though male sex has previously been associated with low TREC
(17). A similar trend has been seen in multiple other states, where
the proportion of males among infants with TCL ranged from 59
to 76% (2). Furthermore, our study excluded premature infants
whose newborn screens normalized after 36 weeks, so the
increased incidence of prematurity among males compared to
females would not be expected to inﬂuence our results. The
proportion of African-American infants in our study population
(33%) was also higher than in the general population. This was
observed in New York state as well where Vogel et al. found that
41.6% of infants with positive newborn SCID screens were
African-American (16). However, a larger study from
California showed no association between ethnicity and
newborn SCID screen outcome (3). Therefore, further studies
will be needed to determine whether ethnic differences in
neonatal thymic function and lymphopoiesis exist that could
be a risk factor for having a positive newborn screen.
As with any form of population wide screening, the newborn
SCID screen has revealed signiﬁcant phenotypic diversity,
especially in its detection of non-SCID TCL. In our study
group, the screening led to identiﬁcation of novel genetic
variants in FOXN1, TBX1, MYSM1, POLD1, and CD3E
associated with non-SCID TCL. To our knowledge these
variants had not been previously reported in the literature at
the time of diagnosis. FOXN1 plays a regulatory role in thymic
epithelial cell development, such that FOXN1 haploinsufﬁciency
has been shown to result in neonatal TCL that gradually
improves with age (18). This has so far been the case for our
patient with the FOXN1 variant (P2). Loss-of-function variants
in TBX1 have previously been reported in patients with
DiGeorge syndromic features and TCL, but without 22q11

Perinatal Complications and Birth Weight
Roughly a third of all patients (N=54) had a prenatal or perinatal
complication. The most common were neonatal respiratory
distress syndrome or oxygen requirement (N=16), either
chronic or gestational maternal diabetes (N=13), maternal
hypertension or pre-eclampsia (N=10), and intrauterine
recreational drug exposure (N=8). Four infants were born to
mothers who had received betamethasone for threatened
preterm labor, otherwise none had been exposed to any other
immunosuppressant medications in utero. Three of these
patients had normal CD3+ T cell counts, including 1 with B
cell and CD4 lymphopenia, and the fourth had non-SCID TCL
due to partial DiGeorge syndrome. There was no signiﬁcant
difference in initial CD3 count (2668 ± 1186 vs. 2452 ± 1387
cells/mL, p=0.35) or total TREC copies (13385 ± 7431 vs. 13809 ±
8360 copies/10 6 T cells, p=0.77) between infants with
complications and those without. The incidence of any form of
TCL was 37% among infants with complications and 41% among
those without.
Birth weights were available from chart review for 139 of the
154 total patients. Of these, 20 (14%) were characterized as low
birth weight at less than 2500 grams. Comparison between low
and normal weight infants showed no signiﬁcant differences in
CD3 counts (2706 ± 1241 vs. 2477 ± 1341 cells/mL, p=0.43) or
TREC copies (13704 ± 9520 vs. 14331 ± 8031 copies/106 T cells,
p=0.81). Additionally, both groups had the exact same
prevalence of TCL of 40%.

DISCUSSION
Our study reviewed the immunologic phenotypes of 154 infants
with positive SCID newborn screens referred from both Illinois,
where SCID screening started in 2014, and Missouri, where it
started in 2017. These infants represent a third of total Missouri
referrals and an unknown portion of Illinois referrals, with
choice of referral site determined by patient/family and
primary care provider preference. Over a total 6-year period,
SCID screening detected CD3+ TCL of varying degrees in 39% of
the study population, including 33% with non-SCID TCL and
6% with SCID or other severe forms of TCL. Although our
institution receives only a third of the total statewide referrals for
abnormal newborn screens, these rates are consistent with the
unpublished statewide data from Missouri in 2019 which showed
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deﬁnitive cure at this time for ataxia-telangiectasia, the overall
beneﬁt of early diagnosis remains controversial. However, these
cases illustrate the ability of newborn SCID screening to detect not
only SCID, but other conditions associated with TCL earlier than
they might otherwise be diagnosed. This has the potential to allow
for appropriate interventions to be instituted prior to the onset of
other disease complications.
Longitudinal follow up of idiopathic TCL in our study
revealed favorable outcomes overall. T cell counts rose over
time in 75% of infants, and even normalized in 25% at the
median age of 5 months (range 2.5 to 26 months). These patients
had fewer infectious complications compared to those with a
known genetic cause of non-SCID TCL. Additionally, none of
the infants with idiopathic TCL required antibiotic prophylaxis
or immunoglobulin replacement. These ﬁndings are reassuring
as idiopathic TCL remains a diagnosis of exclusion, and one for
which the optimal monitoring, management strategies and longterm prognosis are still being deﬁned. In the future, more
extensive genetic testing of these infants may reveal new
etiologies for lymphopenia, allowing for less testing and
monitoring in the cases where there are no long-term
consequences of TCL. Our study was limited by the fact that
half of infants with idiopathic TCL did not undergo genetic
testing, as it was not considered clinically indicated given the
milder degree of lymphopenia in these infants and the positive
trend in their T cell counts over time. Additionally, only 13 of 51
infants with non-SCID TCL were inpatients at the time of initial
evaluation. The fact that the majority of patients recruited in our
study were outpatients could potentially explain the lower
incidence of secondary causes of TCL in our cohort compared
to prior studies, since patients with lymphopenia due to
conditions like gastroschisis, thymectomy, or other secondary
causes would be more likely diagnosed in the inpatient setting.
Infants diagnosed with typical SCID by newborn screening
beneﬁted from earlier diagnosis and improved transplant
outcomes compared to those d iagnosed before the
implementation of routine screening (median age at diagnosis of
9 days versus 10 months, respectively). Three out of the 4 infants
diagnosed prior to newborn SCID screening required repeat
transplants, while only 1 of the 6 diagnosed after newborn
screening required a repeat transplant, suggesting greater success
of transplant when performed at an earlier age and prior to the onset
of opportunistic infections that were encountered by the infants
diagnosed prior to newborn SCID screening. This ﬁnding is
consistent with previously published outcomes in transplant for
SCID. In our cohort, differences may also be inﬂuenced by
differences in duration of follow up between the two groups
(median age at most recent follow up of 5 years versus 3 years in
the groups diagnosed before and after routine screening,
respectively), however the rate of graft failure at 6 months posttransplant was also greater prior to newborn SCID screening (1 out
of 4) than afterward (1 out of 6). Although nearly all infants with
leaky SCID were diagnosed within the ﬁrst month of life by
newborn screening, they were transplanted at later ages than
infants with typical SCID due to longer times to establish
deﬁnitive genetic diagnosis or evidence of continued T cell

deletion (19). However, our patient with a TBX1 variant (P3) did not
have any physical features of velocardiofacial syndrome, only
diminished lymphopoiesis. P4 on the other hand also had a TBX1
variant but had congenital heart defects and TCL that later
normalized. The patient with a novel MYSM1 variant (P1)
suffered worsening pancytopenia and unfortunately died from
post-transplant complications. This gene encodes a histone
deubiquitinase that controls expression of transcription factors
involved in hematopoiesis and lymphocyte differentiation.
Homozygous missense and nonsense variants leading to MYSM1
deﬁciency have previously been reported in patients presenting with
bone marrow failure and B cell lymphopenia (20, 21).
Some of the infants in our study who had syndromes associated
with non-SCID TCL presented to medical attention solely based on
their abnormal newborn SCID screens, highlighting the ability of
SCID screening to facilitate earlier diagnosis and management of
these conditions. For example, 22q11 deletion was the most
common genetic cause for non-SCID TCL, and a quarter of the
infants with this diagnosis in our cohort had no other characteristic
ﬁndings of the disease besides TCL detected by newborn screen.
One of these patients was subsequently diagnosed with a signiﬁcant
congenital heart defect, which might not have otherwise been
detected in a timely manner allowing for treatment. However, the
57% positivity rate of newborn SCID screening for infants with
DiGeorge syndrome at our institution indicates that a normal
newborn screen does not exclude DiGeorge syndrome. Since our
institution’s DiGeorge syndrome population primarily includes
patients with associated complications such as congenital heart
disease who require hospital based care, the DiGeorge syndrome
population as a whole including undiagnosed individuals with
milder features would likely have a lower SCID screen positivity
rate than observed in our study. Additionally, it is to be determined
in a larger cohort if SCID newborn screening impacts long-term
outcomes of incomplete DiGeorge syndrome patients as the data
from our cohort showed no difference in median age at diagnosis
between DiGeorge syndrome infants with abnormal SCID screens
and normal SCID screens. Our ﬁndings also suggest infants with
DiGeorge syndrome and abnormal SCID screens had lower T cell
counts compared to infants with DiGeorge syndrome and normal
SCID screens. However, this is likely confounded by a later age at
immune evaluation in infants with normal SCID screens.
Another example of earlier disease diagnosis due to detection of
non-SCID TCL is the infant diagnosed with ataxia-telangiectasia at
6 months age (P5) as a result of workup for his B and T cell
lymphopenia that were uncovered by follow-up testing for an
abnormal newborn screen. The diagnosis was made prior to the
onset of any other disease manifestations, and allowed for early
diagnosis of his identical twin brother as well, who interestingly had
a normal newborn screen TREC value. The diagnosis of ataxiatelangiectasia by newborn SCID screening was also demonstrated in
4 patients in Ontario, Canada, and shown to be associated with
more severe immunologic and neurologic involvement as
compared to individuals diagnosed later in life. However, earlier
diagnosis also prompted earlier referral to other specialty services as
well as family genetic counseling and screening for malignancies in
the carriers of the ATM variants (22). Given that there is no
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patients were recruited outpatient which led to an
underestimated number of patients with TCL from secondary
causes. The small-size cohort also limited the ability to assess the
signiﬁcance of other factors including prenatal/perinatal
complications and birth weight that may affect TREC levels.
In conclusion, our study adds to the current literature on
newborn SCID screening by demonstrating novel genetic variants
associated with non-SCID TCL and identifying correlations
between various measures of thymic output that may guide the
future laboratory workup and interpretation of infants with positive
SCID screening. SCID newborn screen detected approximately half
of patients with DiGeorge syndrome during neonatal period. It also
strengthens and adds to the observation that idiopathic TCL, as
opposed to non-SCID TCL with known genetic or secondary
causes, generally has a benign clinical course by showing lower
incidence of infections, greater chance of rising T cell count over
time, and greater degree of similarity with healthy infants in terms of
TREC and naïve T cell production. As newborn SCID screening
undoubtedly continues to reveal individuals with non-SCID TCL,
our understanding of T cell development and the numerous factors
that inﬂuence it will continue to grow.

decline and evident hematopoietic defect. One patient with RAG1
mutation was delayed due to logistics related to transfer from
outside institution. One patient had no identiﬁed genetic defect
and proceeded to transplant only after continued decline in T cells
and evidence of hematopoietic defect based on research studies at
National Institutes of Health.
The cutoff levels for a high-risk abnormal newborn screen –
cycle threshold greater than 39 in Missouri or TREC level less
than 25 copies/mL in Illinois – were highly speciﬁc; only 1 out of
the 21 infants with high-risk screens in our cohort had a normal
immune workup. However, one of the patients with leaky SCID
due to IL2RG mutation was missed by newborn screening (14), a
reminder that SCID screening is not 100% sensitive. Infants with
false-positive newborn screens had normal TREC copy number
analysis normalized to CD3+ T cell count, which may be
explained by differences in TREC cutoff values for TREC
quantitation and limitations related to using dried blood spot
samples, although both methods involve real-time PCR. Whereas
the newborn screen reﬂects the TREC copies per microliter of
blood in the dried blood spot specimen, the repeated TREC
analysis reﬂects TREC copies per million cells in a puriﬁed CD3+
T cell population and therefore is more speciﬁc.
The laboratory workup of infants referred for positive
newborn SCID screens at our institution allowed for the
observation that certain immunologic parameters had stronger
positive correlations than others. When comparing TREC copies
normalized to CD3 count and CD4RTE, CD4RTE had a stronger
positive correlation with the CD3 count and naïve Th cell
percentage; however, all were statistically signiﬁcant
correlations. Therefore, this ﬁnding does not diminish the
utility of TREC based screening for assessment of T cell count
in newborns, but provides support for considering CD4RTE as
part of the evaluation of an infant with a positive newborn SCID
screen. In addition, the comparison of these lab parameters
between patient groups showed greater differences in TREC
copies, CD4RTE, and naïve Th cell percentage between the
non-SCID TCL with known genetic cause and normal groups
than between the idiopathic TCL and normal groups. Despite the
mildly decreased net thymic output in idiopathic TCL, these
infants demonstrated relatively normal T cell function as they
generally did not develop recurrent or severe infections.
Despite a third of infants in the study having a prenatal or
perinatal complication, there were no signiﬁcant difference in T cell
counts or TREC copies between these infants and those without
complications. Similarly, no signiﬁcant differences were seen in
these parameters between low birth weight infants and normal
weight infants. However, this is limited by the fact that only 14% of
the infants in the study had low birth weight. Since the association
between birth weight and TRECs is more pronounced with lower
gestational age, the exclusion of premature infants in our study may
also obscure this relationship (23).
We acknowledge several limitations of our study. Our
ﬁndings represent only a subset of infants with abnormal SCID
screen from Illinois and Missouri during the study period and, as
mentioned above, we were unable to assess the total number of
infants screened in both states during the study period. Most
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